Hawkins Matthew J. sold $2.4M of WAY

Hawkins Matthew J. (Chief Executive Officer) sold 82,500 shares of Waystar Holding Corp. (WAY) at $28.75 ($2.37M total) on 2026-11-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hawkins Matthew J.
Published Nov 10, 2026, 10:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$WAY
Bearish
high confidence
Mentioned
$WAY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$WAYBearishLow
01

Why it matters

The disclosure provides fresh, material information that may influence short‑term price dynamics.

02

Market read

Insider sales by top executives are closely watched; this filing could prompt traders to reassess Waystar's near‑term outlook.

03

What to watch

Potential upcoming corporate actions or financing needs that prompted the insider to free cash.

Relevance 5/10Novelty 7/10Timing: after‑hours today

Background

Waystar Holding Corp. (NASDAQ: WAY) filed a Form 4 reporting a $2.37 million sale of shares by its CEO under a 10b5‑1 plan.

Company-level read

Ticker impact

$WAYBearishHigh confidence
Context

CEO Hawkins Matthew J. sold 82,500 shares for $2.37M via a 10b5‑1 plan, reducing his stake to 1.8M shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A $2.4M open‑market sale by the chief executive is a material event for a mid‑cap stock and typically triggers short‑term selling pressure.

Market effects

Minimal; the sale is company‑specific and does not affect the broader healthcare services sector.

Limited to U.S. investors tracking Waystar; no broader regional effect.

Low; the filing is a routine insider transaction without global macro implications.

Counterpoint

The sale could be a routine liquidity event under a pre‑arranged plan, not necessarily a negative signal.

Key entities

  • Waystar Holding Corp.

    Healthcare technology firm whose CEO executed an insider sale.

  • Hawkins Matthew J.

    Chief Executive Officer of Waystar, seller of the shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WAYHighAI 8/10

Why is Waystar stock sliding today?

Waystar Holding Corp (WAY) stock fell 4.1% in pre-market trading after Q3 earnings. Revenue rose 21% YoY to $325.6M, and adjusted EPS of $0.44 beat estimates. However, full-year 2026 revenue guidance missed expectations, with a midpoint of $1.282B below the $1.29B consensus. Analysts raised price targets but cited concerns over Q4 growth deceleration.

$WAYHighAI 8/10

Waystar Holding Corp (WAY) Q3 2026 Earnings Call Highlights: Revenue Jumps 21% as AI Bookings Surge

Waystar Holding Corp (WAY) reported Q3 2026 revenue growth of 21% YoY, with adjusted EBITDA up 24% and a 43% margin. Bookings surged 25% YoY, including a major client win. AI innovations drove 43% of Q3 bookings. However, Q4 revenue growth is expected to slow to ~6%, with adjusted EBITDA declining sequentially due to top-line variability and AI investments. Iodine's performance-based pricing model delayed revenue recognition. Net revenue retention was 108%, at the lower end of historical range.

$WAYMed

Waystar: Q3 Earnings Snapshot

Waystar Holding Corp. (WAY) reported Q3 earnings of $31M, or 16 cents per share, beating estimates. Adjusted EPS was 44 cents. Revenue was $325.6M, also exceeding forecasts. The company expects full-year EPS of $1.63-$1.71 and revenue of $1.28B-$1.29B.

$WAYHighAI 8/10

What Waystar (WAY) Said on Its Q3 Earnings Call

Waystar (WAY) reported Q3 bookings for Iodine exceeded year-to-date plans by 74%, with $15M in Q3 bookings. The company launched an autonomous claim-resubmission feature, estimating it could resubmit up to $5B in rejected claims annually. Waystar lowered its full-year revenue forecast to $1.277B-$1.287B but raised adjusted EBITDA guidance to $543M-$549M. The company cited timing pressures for the revenue outlook adjustment.